Suchergebnisse - "Perrone, Francesco"

PubPharm (403)

21

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021

enthalten in: JAMA network open | 2023

von Ciani, O. | Meregaglia, M. | De Lorenzo, F. | +2

22

Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab

enthalten in: Clinical Pharmacology & Therapeutics | 2023

von Polano, M. | Bedon, L. | Dal Bo, M. | +19

23

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

enthalten in: JAMA network open | 2022

von Bartoletti, M. | Pignata, S. | Lorusso, D. | +3

24

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer : a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

enthalten in: British journal of cancer | 2022

von Musacchio, L. | Califano, D. | Bartoletti, M. | +26

25

Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018

enthalten in: The European journal of health economics | 2022

von Lillini, R. | De Lorenzo, F. | Baili, P. | +7

26

The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer : A Systematic Review and Meta-Analysis

enthalten in: Cancers | 2022

von Caminiti, C. | Maglietta, G. | Diodati, F. | +5

27

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial

enthalten in: bioRxiv.org | 2022

von Perrone, F. | Piccirillo, M. | Ascierto, P. | +33

28

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC : The BEVERLY Multicenter Randomized Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Piccirillo, M. | Bonanno, L. | Garassino, M. | +30

29

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab

enthalten in: Diagnostics (Basel, Switzerland) | 2022

von Fabbi, M. | Costa, D. | Russo, D. | +19

30

Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer : phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2022

von Schettino, C. | Musacchio, L. | Bartoletti, M. | +14